The Peru Cervical Cancer Prevention Study (PERCAPS): the technology to make screening accessible
Kimberly L Levinson, Carolina Abuelo, Jorge Salmeron, Eunice Chyung, Jing Zou, Suzanne E Belinson, Guixiang Wang, Carlos Santos Ortiz, Carlos Santiago Vallejos, Jerome L Belinson, Kimberly L Levinson, Carolina Abuelo, Jorge Salmeron, Eunice Chyung, Jing Zou, Suzanne E Belinson, Guixiang Wang, Carlos Santos Ortiz, Carlos Santiago Vallejos, Jerome L Belinson
Abstract
Objective: This study utilized a combination of HPV self-sampling, iFTA elute specimen cards, and long distance transport for centralized processing of specimens to determine the feasibility of large-scale screening in remote and transient populations.
Methods: This study was performed in two locations in Peru (Manchay and Iquitos). The "Just For Me" cervico-vaginal brush and iFTA elute cards were used for the collection and transport of specimens. Samples were shipped via FedEx to China and tested for 14 types of high-risk HPV using PCR based MALDI-TOF. HPV positive women were treated with cryotherapy after VIA triage, and followed-up with colposcopy, biopsy, ECC, and repeat HPV testing at 6 months.
Results: Six hundred and forty three women registered, and 632 returned a sample over a 10 day period. Within 2 weeks, specimens were shipped, samples tested, and results received by study staff. Sixty-eight women (10.8%) tested positive, and these results were delivered over 4 days. Fifty-nine HPV positive women (87%) returned for evaluation and treatment, and 2 had large lesions not suitable for cryotherapy. At 6 months, 42 women (74%) returned for follow-up, and 3 had CIN 2 (all positive samples from the endocervical canal). Ninety eight percent of participants reported that they would participate in this type of program again.
Conclusions: Utilizing HPV self-sampling, solid media specimen cards for long distance transport, and centralized high throughput processing, we achieved rapid delivery of results, high satisfaction levels, and low loss to follow-up for cervical cancer screening in remote and transient populations.
Trial registration: ClinicalTrials.gov NCT01338051.
Conflict of interest statement
Conflict of Interest Statement:
Preventive Oncology International has received support in kind (reagents and testing) and/or funds for direct support and research from Hologic Inc., Qiagen, Gen-Probe, Merck Inc., BGI Shenzhen, and GE Healthcare.
Copyright © 2013 Elsevier Inc. All rights reserved.
Figures
Source: PubMed